161 related articles for article (PubMed ID: 1103333)
1. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.
de Palo GM; de Lena M; Di Re F; Luciani L; Valagussa P; Bonadonna G
Surg Gynecol Obstet; 1975 Dec; 141(6):899-902. PubMed ID: 1103333
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma.
De Palo GM; De Lena M; Bonadonna G
Cancer Treat Rep; 1977; 61(3):355-7. PubMed ID: 326402
[No Abstract] [Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
4. Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo.
Tropé C; Sigurdsson K
Neoplasma; 1982; 29(3):309-14. PubMed ID: 7133226
[TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
7. Melphalan with and without doxorubicin in advanced ovarian cancer.
Tropé C
Obstet Gynecol; 1987 Oct; 70(4):582-6. PubMed ID: 3306509
[TBL] [Abstract][Full Text] [Related]
8. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
Bruckner HW; Pagano M; Falkson G; Creech R; Arseneau JC; Horton J; Brodovsky H; Davis TE; Slayton RW; Greenspan E
Cancer Treat Rep; 1979 Feb; 63(2):297-9. PubMed ID: 376136
[No Abstract] [Full Text] [Related]
9. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
Omura GA; Morrow CP; Blessing JA; Miller A; Buchsbaum HJ; Homesley HD; Leone L
Cancer; 1983 Mar; 51(5):783-9. PubMed ID: 6401594
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
[TBL] [Abstract][Full Text] [Related]
11. [Combination of adriamycin and cis-diammine-dichloro-platinum (II) in the treatment of advanced, therapy-resistant, ovarian carcinoma (author's transl)].
Cavalli F; Stoller U; Tschopp L; Sonntag RW; Brunner KW
Dtsch Med Wochenschr; 1978 Jun; 103(22):927-31. PubMed ID: 350534
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Thigpen JT; Buchsbaum HJ; Mangan C; Blessing JA
Cancer Treat Rep; 1979 Jan; 63(1):21-7. PubMed ID: 369691
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary report on the treatment of ovarian cancer with adriamycin following full conventional treatment (author's transl)].
Wolf A; Vahrson H
Geburtshilfe Frauenheilkd; 1977 Mar; 37(3):224-7. PubMed ID: 858485
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Büyükünal E; Derman U; Serdengecti S; Berkarda B
Chemioterapia; 1987 Oct; 6(5):377-9. PubMed ID: 3322590
[TBL] [Abstract][Full Text] [Related]
16. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
[TBL] [Abstract][Full Text] [Related]
18. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
19. Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.
Smith JP; Rutledge FN
Natl Cancer Inst Monogr; 1975 Oct; 42():169-72. PubMed ID: 825778
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole.
Coleman CN; Carlson RW; Artim RA; Sampson WI; Lawrence HJ; Wong P; Halsey J; Kohler M; Gribble M; Sikic BI
Cancer Res; 1988 Jun; 48(12):3528-32. PubMed ID: 2836059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
